Company Profile

Company Description

This biopharmaceutical firm focuses on developing innovative therapies to treat chronic liver diseases, fibrosis, and cancer. Their research centers on galectin proteins, which play a key role in inflammation and tissue scarring. By targeting these proteins, they aim to create breakthrough treatments for conditions like non-alcoholic steatohepatitis (NASH) and certain solid tumors. Their pipeline includes both small-molecule inhibitors and carbohydrate-based compounds designed to modulate disease progression. The company collaborates with academic and industry partners to advance its clinical-stage programs. Their work holds promise for addressing unmet medical needs in complex diseases with limited treatment options.